CAMBRIDGE, Mass., Jan. 2, 2024 /PRNewswire/ NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation.
NeuroBo Pharmaceuticals, Inc. NRBO shares are trading lower in Friday's premarket session after ending Thursday's session with a whopping 21.2% gain. The…
NeuroBo Pharmaceuticals, Inc. (NRBO), a clinical-stage biotechnology company, Thursday said it has submitted Investigational New Drug or IND application to FDA, regarding Phase 1 clinical trial of DA-1726 for the treatment of obesity.
CAMBRIDGE, Mass., Dec. 28, 2023 /PRNewswire/ NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has.